文章题目：AdjuvantNivolumabinResectedEsophagealorGastroesophagealJunctionCancer
研究人员：RonanJ.Kelly,etal.
发表时间：April1,
期刊名称：NEJM
影响因子：74.
1、核心亮点
Amongpatientswithresectedesophagealorgastroesophagealjunctioncancerwhohadreceivedneoadjuvantchemoradiotherapy,disease-freesurvivalwassignificantlylongeramongthosewhoreceivednivolumabadjuvanttherapythanamongthosewhoreceivedplacebo.
在接受过新辅助放化疗的食管癌或胃食管结合部癌切除术后患者中，接受纳武利尤单抗辅助治疗的患者的无病生存期显著超过接受安慰剂的患者。
2、Abstract：
BACKGROUND
Noadjuvanttreatmenthasbeenestablishedforpatientswhoremainathighriskforrecurrenceafterneoadjuvantchemoradiotherapyandsurgeryforesophagealorgastroesophagealjunctioncancer.
METHODS
WeconductedCheckMate,aglobal,randomized,double-blind,placebo-controlledphase3trialtoevaluateacheckpointinhibitorasadjuvanttherapyinpatientswithesophagealorgastroesophagealjunctioncancer.Adultswithresected(R0)stageIIorIIIesophagealorgastroesophagealjunctioncancerwhohadreceivedneoadjuvantchemoradiotherapyandhadresidualpathologicaldiseasewererandomlyassignedina2:1ratiotoreceivenivolumab(atadoseofmgevery2weeksfor16weeks,followedbynivolumabatadoseofmgevery4weeks)ormatchingplacebo.Themaximumdurationofthetrialinterventionperiodwas1year.Theprimaryendpointwasdisease-freesurvival.
RESULTS
Themedianfollow-upwas24.4months.Amongthepatientswhoreceivednivolumab,themediandisease-freesurvivalwas22.4months(95%confidenceinterval[CI],16.6to34.0),as
